As biopharma companies and the U.S. government near the deadline of their drug price talks under the Inflation Reduction Act (IRA),...
2 months ago

The Swiss drugmaker said the stoppage is necessary to conform with new regulatory limits on nitrosamine, but will not affect commercial...
5 months ago

We are increasing our fair value estimate for Eli Lilly LLY to $580 per share from $540 following better-than-expected second-quarter results.
2 months ago

On Wednesday, BofA Securities adjusted its stance on Novartis (NOVN:SW) (NYSE: NVS) stock, downgrading the pharmaceutical giant from Buy to...
1 month ago

Novartis reports strong Q2 results with adjusted EPS of $1.97, up 21% YoY, and sales at $12.51 billion, up 11%. Key drivers include Entresto...
2 months ago

Entresto may be subject to a negotiated price in Medicare Part D for one year before it will be excused because of generic competition.
8 months ago

Novartis' (NVS) key drugs, Entresto, Kisqali and Pluvicto, are likely to have fueled its top and bottom-line numbers in the fourth quarter.
8 months ago

An analysis of the investment activity of Novartis in recent years.
6 months ago

The U.K. National Institute for Health and Care Excellence rejected Novartis AG's Kisqali for treating a type of breast cancer in a draft...
65 months ago

Novartis has pulled back the curtains on the highly anticipated Kisqali data that previously drove an 8% share-price rally in a single day.
16 months ago